Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Atenolol/nitrendipine/folic-acid compound medicine combination and use thereof

A technology of nitrendipine and a composition, which is applied in the field of pharmaceutical compositions of atenolol/nitrendipine/folate compounds, can solve the problems of increased heart rate reflex, large differences in blood pressure and heart rate among individuals, etc., and achieves lower blood pressure. , weaken the effect of slowing down the heart rate and prolong the duration of blood pressure

Inactive Publication Date: 2009-05-06
史克勇
View PDF0 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the drug can cause heart rate reflex acceleration, and this side effect lasts for up to 12 hours, and the blood pressure and heart rate measured at the same time after the volunteers take the drug vary greatly from individual to individual (Dang Aimin, Du Jiangbo, Zhang Yuqing, etc. Bayer-Nitrendipine Pharmacokinetics and Pharmacodynamics in Healthy Humans. Clinical Metaphysics. 1999; 14: 582-583.)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Atenolol/nitrendipine/folic-acid compound medicine combination and use thereof
  • Atenolol/nitrendipine/folic-acid compound medicine combination and use thereof
  • Atenolol/nitrendipine/folic-acid compound medicine combination and use thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0032] Example 1 Preparation of Atenolol 10mg / Nitrendipine 5mg / Folic Acid 0.2mg Tablets

[0033] prescription

[0034]

[0035]

[0036] Preparation Process:

[0037] (1) Take the prescribed amount of atenolol, nitrendipine and folic acid and pass through a 100-mesh sieve and mix them uniformly by the method of increasing in equal amounts for later use;

[0038] (2) Other auxiliary materials are passed through a 100-mesh sieve and dried at 75°C for 2 hours;

[0039] (3) Mix the starch, microcrystalline cellulose, and CMS.Na according to the prescription amount, and then mix them evenly with the mixed raw material drug in equal increments;

[0040] (4) Add an appropriate amount of binder to prepare soft materials, granulate with a 24-mesh sieve, granulate with a 20-mesh sieve, and dry at 40-75°C.

[0041] (5) Add an appropriate amount of magnesium stearate to the dry granules and mix evenly. After the content is determined, compress into tablets and pack.

[0042] 1 t...

Embodiment 2

[0043] Example 2 Preparation of Atenolol 20mg / Nitrendipine 10mg / Folic Acid 0.8mg / Leucovorin 0.8mg Capsules

[0044] prescription

[0045]

[0046] Preparation Process:

[0047] According to the prescription ratio, take lactose, microcrystalline cellulose, starch, and carboxymethyl starch sodium and dry them at about 100°C for about 2 hours, pass through a 100-mesh sieve; pass the raw material through a 100-mesh sieve, and increase the amount of the above-mentioned excipients in equal increments Mix well and fill the capsules.

[0048] 1 time a day, 1-2 capsules each time.

Embodiment 3

[0049] Example 3 Preparation of Atenolol 50mg / Nitrendipine 25mg / Levofolinate Calcium 0.4mg Sustained Release Tablets

[0050] prescription

[0051]

[0052] Preparation Process:

[0053] According to the proportion of the prescription, the raw material is mixed with hypromellose, citric acid is dissolved in ethanol as a wetting agent to make a soft material, granulated, dried, sized, mixed with magnesium stearate, pressed Slice and serve.

[0054] 1 time every other day, 1-2 tablets each time.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a medicament compound of an atenolol / nitrendipine / folacin compound, and usages thereof. The invention belongs to the technical field of pharmacy. The medicament compound contains the atenolol of theriacal dosage, the nitrendipine of theriacal dosage, the folacin compound of theriacal dosage and a vector acceptable on pharmacy. The dosage of the atenolol is 5 to 50mg; the dosage of the nitrendipine is 3 to 30mg; and the dosage of the folacin compound is 0.2 to 1.6mg. The invention has the advantages that the medicament compound enhances the curative effect of pressure reduction, prolongs the lasting time of pressure reduction and removes the side effect of quickening the cardiac rate of the reflectivity of the nitrendipine in the compound by the multi-target spot cooperative pressure reduction effect; more importantly, the medicament compound can effectively prevent, cure or ease a plurality of complicating diseases of hypertension and cardiovascular and cerebrovascular diseasesin such as stroke and the like by double target spots (Hcy, blood pressure) on the foundation of reducing the side effects. Moreover, the medicament compound can lead a sufferer to be convenient to take the medicine.

Description

technical field [0001] The invention relates to a pharmaceutical composition of atenolol / nitrendipine / folic acid compound and its application, belonging to the technical field of pharmacy. Background technique [0002] Hypertension is divided into essential hypertension (hypertension, accounting for about 90%) and secondary hypertension (symptomatic hypertension). The prevalence of hypertension is approximately 20% in adults. The direct complications of hypertension include cerebrovascular accident, renal failure, heart failure, etc. Most of these complications can cause disability or death. Generally speaking, the average life expectancy of hypertensive people is 15-20 years shorter than that of normal people. Malignant hypertension, if left untreated, can cause death within a year. The first-line antihypertensive drugs recommended by WHO and my country's hypertension treatment guidelines are: calcium antagonists, RAS inhibitors (including AT1 receptor antagonists and AC...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/435A61K31/165A61P9/12A61P9/10A61P9/00
Inventor 史克勇徐艺兰苏定冯
Owner 史克勇
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com